CAMBRIDGE, Mass.--(OvaScienceSM, a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced the appointment of Thomas Malley to its Board of Directors.)--
“I look forward to working closely with management and the Board to realize the value of OvaScience’s egg precursor cell platform to generate new product opportunities.”
“Tom’s knowledge of the healthcare industry and his expertise in identifying companies with breakthrough technologies will be invaluable to OvaScience as we seek to develop and commercialize new treatments for infertility,” said Michelle Dipp, M.D., Ph.D., Chief Executive Officer and Co-Founder of OvaScience.
Since 2007, Mr. Malley has served as President of Mossrock Capital, a private investment firm in Denver. Prior to Mossrock Capital, Mr. Malley served in various roles at Janus Mutual Funds for 16 years. From 1999 to 2007, Mr. Malley started and served as the Portfolio Manager of the Janus Global Life Sciences Fund and served as Vice President of the Janus Healthcare team. Prior to that, he served as an equity analyst for Janus from 1991 to 1998, covering healthcare and biotechnology, telecommunications, gaming and lodging, and housing stocks. Mr. Malley currently serves on the Board of Directors of publicly traded biotechnology firms Synageva Biopharma Corp. and Puma Biotechnology, Inc. Previously, he served on the Board of Cougar Biotechnology, Inc. from 2007 to 2009, prior to the company’s acquisition by Johnson and Johnson. Mr. Malley holds a B.S. in biology from Stanford University.
“OvaScience is driving innovation in an area of healthcare where new approaches are needed to improve the treatment of infertility,” said Mr. Malley. “I look forward to working closely with management and the Board to realize the value of OvaScience’s egg precursor cell platform to generate new product opportunities.”
OvaScience is a life sciences company focused on the discovery, development and commercialization of new treatments for infertility. The Company’s patented technology is based on the discovery of egg precursor cells (EggPCSM), which are found in the ovaries. By applying proprietary technology to identify and purify EggPCs, AUGMENTSM aims to improve egg quality and increase the success of in vitro fertilization (IVF). OvaScience’s team of scientists, physicians and advisers includes recognized leaders in the field of reproductive medicine.